Definitive Healthcare Corp. — Cyborg Score 5/10

Mixed
Healthcare Data & Analytics / SaaS / Healthcare Technology

Strategic Profile

The company positions itself as an industry leader in healthcare market data and analytics with differentiated data assets, AI analytics capabilities, and integration partnerships. Despite current profitability challenges and revenue pressures (2026 guidance projects $220-226M, down from $241.5M in 2025), management emphasizes strategic investments in data infrastructure, customer success initiatives, and retention to support long-term margin expansion and market share gains.

Cyborg Score Rationale

Definitive Healthcare demonstrates solid market positioning in healthcare intelligence with strong data assets, high customer value, and solid adjusted EBITDA margins (29% in 2025). However, the company faces significant headwinds including declining revenue guidance for 2026, a major goodwill impairment ($196.1M in 2025), current unprofitability, and compressed margins due to intensifying competition from AI tools and restricted customer IT budgets.

Top Insights

  • 2025 full-year revenue of $241.5M with adjusted EBITDA of $70.4M (29% margin) and $54.9M unlevered free cash flow demonstrates underlying business strength despite profitability challenges
  • 2026 guidance shows revenue decline to $220-226M and EBITDA compression to $53-58M, reflecting customer budget pressures and competitive intensity in the healthcare data space
  • Company recorded substantial $196.1M goodwill impairment in 2025, signaling past acquisition missteps and potential valuation concerns that may persist
  • Management execution focus on enhancing data differentiation, customer retention initiatives, and digital partnerships represents strategic pivot but must overcome commodity AI competition and data privacy regulatory headwinds

Named Competitors

  • Healthcare Workforce Management — Healthcare IT training and workforce analytics
  • Clinical Data Analytics — Healthcare data analytics and insights platform
  • Pharma/Biotech Analytics — Pharma and biotech modeling and analytics

Recent Developments

  • (February 2026) Reported Q4 2025 results: $61.5M quarterly revenue, $241.5M full-year, significant goodwill impairment, 2026 guidance below 2025 levels
  • (January 2026) CFO Casey Heller presenting at Needham Growth Conference on strategic positioning and operational simplification
  • (July 2025) Hired Chief Commercial Officer and Chief HR Officer with inducement equity grants, indicating leadership restructuring and focus on go-to-market execution

Open the full interactive Definitive Healthcare Corp. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →